View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Sunitinib 37.5, Pheochromocytoma / Paraganglioma
Protocol-ID: 2485 V1.0 (Mini), SUNI37.5, Pheochromocytoma/ParagangliomaIndication(s)
- Malignant Pheochromocytoma; ICD-10 C74.1
- Paraganglioma; ICD-10 C75.5
Links
- The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter study which aims to determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing). [clinicaltrials.gov]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 11.11.2023